<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Hemogenyx Pharmaceuticals Plc — News on 6ix</title>
    <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc</link>
    <description>Latest news and press releases for Hemogenyx Pharmaceuticals Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 28 Apr 2026 06:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/hemogenyx-pharmaceuticals-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e43b78dffbe2df1279c6.webp</url>
      <title>Hemogenyx Pharmaceuticals Plc</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc</link>
    </image>
    <item>
      <title>Institutional Fundraise</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/institutional-fundraise</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/institutional-fundraise</guid>
      <pubDate>Tue, 28 Apr 2026 06:00:00 GMT</pubDate>
      <description>Hemogenyx Pharmaceuticals plc has successfully raised £3,000,000 through a direct subscription of 374,532 new ordinary shares at £8.01 each, with net proceeds designated to accelerate Phase I clinical trials for its HG-CT-1 therapy, targeting relapsed/refractory acute myeloid leukaemia in adults and children. The company is also progressing its early commercialisation strategy for HG-CT-1 in Estonia, having established the necessary manufacturing hardware and infrastructure and preparing for tec</description>
    </item>
    <item>
      <title>Annual IND Report with FDA</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/annual-ind-report-with-fda</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/annual-ind-report-with-fda</guid>
      <pubDate>Tue, 14 Apr 2026 06:00:00 GMT</pubDate>
      <description>Hemogenyx Pharmaceuticals plc has filed its annual Investigational New Drug (IND) report with the FDA for HG-CT-1, a CAR-T cell therapy for relapsed or refractory acute myeloid leukemia. The report covers the second year of the Phase 1 clinical trial, which aims to enroll up to 36 patients. So far, three adult patients treated at the initial lowest dose level of 7 × 10⁷ CAR⁺ cells have shown CAR-T cell expansion and persistence, blast burden reductions, and no reported immune effector cell-assoc</description>
    </item>
    <item>
      <title>Tech Transfer Completion and Clinical Trial Update</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/tech-transfer-completion-and-clinical-trial-update</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/tech-transfer-completion-and-clinical-trial-update</guid>
      <pubDate>Tue, 31 Mar 2026 12:22:00 GMT</pubDate>
      <description>Hemogenyx Pharmaceuticals plc has successfully completed the technology transfer for its HG-CT-1 CAR-T cell therapy manufacturing to Made Scientific and submitted a comparability data package to the FDA. The company is now ready to commence patient recruitment for its Phase 1 clinical trial in relapsed/refractory acute myeloid leukemia, initiating treatment at an increased dose level for adult patients and the lowest dose level for pediatric patients. This marks a significant advancement in the </description>
    </item>
    <item>
      <title>Total Voting Rights</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/total-voting-rights-732</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/total-voting-rights-732</guid>
      <pubDate>Fri, 27 Feb 2026 08:10:00 GMT</pubDate>
      <description>Hemogenyx Pharmaceuticals plc announced on 27 February 2026 that its total issued share capital comprises 6,425,429 ordinary shares of 1p each, with no shares held in treasury, resulting in a total of 6,425,429 voting rights. This figure serves as the denominator for shareholders to determine notification requirements under the Financial Conduct Authority&apos;s Disclosure Guidance and Transparency Rules regarding their investment or changes in interest in the company&apos;s share capital.
               </description>
    </item>
    <item>
      <title>Holding(s) in Company</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/holdings-in-company-1032</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/holdings-in-company-1032</guid>
      <pubDate>Tue, 24 Feb 2026 07:00:00 GMT</pubDate>
      <description>David John Smith, through various controlled entities including GHC Property Services Limited, HBP Systems Limited, Kamarin Computers Limited, HBP Monpellier Limited, and Copier Systems Limited, has increased his total voting rights in Hemogenyx Pharmaceuticals PLC. As of February 22, 2026, his holding stands at 10.2852% of the voting rights, representing 655,642 shares, a notable increase from his previous notification of 8.0443% on January 9, 2026, and 7.0385% on February 24, 2026. This acquis</description>
    </item>
    <item>
      <title>Exercise of Warrants and Issue of Equity</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/exercise-of-warrants-and-issue-of-equity-17</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/exercise-of-warrants-and-issue-of-equity-17</guid>
      <pubDate>Mon, 23 Feb 2026 07:00:00 GMT</pubDate>
      <description>Hemogenyx Pharmaceuticals plc has announced the exercise of warrants, resulting in the issuance of 50,841 new ordinary shares and raising £118,632 for the company. These new shares, which will rank pari passu with existing ordinary shares, are expected to be admitted to trading on the LSE&apos;s main market around February 27, 2026. Following this admission, the total number of issued shares and voting rights in the company will be 6,425,429.
                Disclaimer*</description>
    </item>
    <item>
      <title>CORRECTION FROM SOURCE: Hemogenyx Pharmaceuticals PLC Announces Issue of Equity</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/correction-from-source-hemogenyx-pharmaceuticals-plc-announces-issue-of-equity</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/correction-from-source-hemogenyx-pharmaceuticals-plc-announces-issue-of-equity</guid>
      <pubDate>Tue, 10 Feb 2026 16:45:00 GMT</pubDate>
      <description>The following amendment has been made to the Issue of Equity&apos; announcement released on 10 February 2026. The sentence &quot;through a direct subscription for 313,333 new ordinary shares in the Company at a price of £7.50 per share&quot; has been corrected ...</description>
    </item>
    <item>
      <title>Hemogenyx Pharmaceuticals PLC Announces Issue of Equity</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-issue-of-equity</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-issue-of-equity</guid>
      <pubDate>Tue, 10 Feb 2026 07:00:00 GMT</pubDate>
      <description>THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT ...</description>
    </item>
    <item>
      <title>Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-update-on-admission-of-shares</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-update-on-admission-of-shares</guid>
      <pubDate>Mon, 22 Dec 2025 08:18:00 GMT</pubDate>
      <description>LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update to the admission of new ordinary shares as announced ...</description>
    </item>
    <item>
      <title>Hemogenyx Pharmaceuticals PLC - Issue of Equity</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-issue-of-equity</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-issue-of-equity</guid>
      <pubDate>Thu, 18 Dec 2025 07:10:00 GMT</pubDate>
      <description>THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT ...</description>
    </item>
    <item>
      <title>Hemogenyx Pharmaceuticals PLC Announces Publication of Prospectus</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-publication-of-prospectus</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-publication-of-prospectus</guid>
      <pubDate>Wed, 19 Nov 2025 12:45:00 GMT</pubDate>
      <description>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION LONDON, UK / ACCESS Newswire / November 19, ...</description>
    </item>
    <item>
      <title>Hemogenyx Pharmaceuticals PLC Announces Clinical Trial Update and Grant of Share Awards</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-clinical-trial-update-and-grant-of-share-awards</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-clinical-trial-update-and-grant-of-share-awards</guid>
      <pubDate>Wed, 29 Oct 2025 07:00:00 GMT</pubDate>
      <description>DSMB Clearance to Proceed to the Next Dose Level of HG-CT-1 in Adult Patients, Opening Pediatric Recruitment, and Grant of Restricted Share Units to Hemogenyx Team LONDON, UK / ACCESS Newswire / October 29, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) ...</description>
    </item>
    <item>
      <title>Hemogenyx Pharmaceuticals PLC Announces Clearance to Initiate Pediatric Enrolment</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-clearance-to-initiate-pediatric-enrolment</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-clearance-to-initiate-pediatric-enrolment</guid>
      <pubDate>Mon, 06 Oct 2025 06:00:00 GMT</pubDate>
      <description>THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT ...</description>
    </item>
    <item>
      <title>Hemogenyx Pharmaceuticals PLC Announces Half-year Report</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-half-year-report</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-half-year-report</guid>
      <pubDate>Tue, 30 Sep 2025 06:00:00 GMT</pubDate>
      <description>Interim Results for the period ended 30 June 2025 LONDON, UK / ACCESS Newswire / September 30, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose Shares ...</description>
    </item>
    <item>
      <title>Hemogenyx Pharmaceuticals PLC Signs Letter of Intent</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-signs-letter-of-intent</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-signs-letter-of-intent</guid>
      <pubDate>Tue, 23 Sep 2025 06:00:00 GMT</pubDate>
      <description>Hemogenyx Pharmaceuticals Signs Letter of Intent with Cellin Technologies to Advance Commercialization of HG-CT-1 CAR-T Therapy in Estonia First Potential Near-Term Revenue Opportunity LONDON / ACCESS Newswire / September 23, 2025 / Hemogenyx Pharmaceuticals ...</description>
    </item>
    <item>
      <title>Hemogenyx Pharmaceuticals PLC Announces Third Patient Safety</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-third-patient-safety</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-third-patient-safety</guid>
      <pubDate>Wed, 17 Sep 2025 06:00:00 GMT</pubDate>
      <description>Third Patient Treated with HG-CT-1 CAR-T Therapy Successfully Passes Initial Safety Evaluation LONDON, UNITED KINGDOM / ACCESS Newswire / September 17, 2025 / Hemogenyx Pharmaceuticals plc is pleased to announce that the third patient has been successfully ...</description>
    </item>
    <item>
      <title>Hemogenyx Pharmaceuticals PLC Announces Invitation to Participate at DCNY Summit</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-invitation-to-participate-at-dcny-summit</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-invitation-to-participate-at-dcny-summit</guid>
      <pubDate>Thu, 11 Sep 2025 07:00:00 GMT</pubDate>
      <description>Hemogenyx Pharmaceuticals Invited to Participate at DCNY Summit LONDON, UK / ACCESS Newswire / September 11, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), is pleased to announce that the Company has been invited to participate and present at the ...</description>
    </item>
    <item>
      <title>Hemogenyx Pharmaceuticals PLC Announces Manufacturing Partnership with Made Scientific</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-manufacturing-partnership-with-made-scientific</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-manufacturing-partnership-with-made-scientific</guid>
      <pubDate>Mon, 08 Sep 2025 06:00:00 GMT</pubDate>
      <description>Hemogenyx Pharmaceuticals Announces Manufacturing Partnership with Made Scientific to Advance HG-CT-1 CAR-T Therapy CITY OF LONDON, GB / ACCESS Newswire / September 8, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), is pleased to announce a manufacturing ...</description>
    </item>
    <item>
      <title>Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-exercise-of-warrants-and-issue-of-equity</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-exercise-of-warrants-and-issue-of-equity</guid>
      <pubDate>Fri, 05 Sep 2025 06:00:00 GMT</pubDate>
      <description>THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT ...</description>
    </item>
    <item>
      <title>Hemogenyx Pharmaceuticals PLC Announces Issue of Convertible Loan Notes</title>
      <link>https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-issue-of-convertible-loan-notes</link>
      <guid isPermaLink="true">https://6ix.com/company/hemogenyx-pharmaceuticals-plc/news/hemogenyx-pharmaceuticals-plc-announces-issue-of-convertible-loan-notes</guid>
      <pubDate>Mon, 01 Sep 2025 14:35:00 GMT</pubDate>
      <description>THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT ...</description>
    </item>
  </channel>
</rss>